Morgan Stanley assumed coverage of Regenxbio (RGNX) with an Overweight rating and $22 price target The firm appreciates the attractiveness of gene therapy in concept for VEGF-mediated diseases given the unmet need, but cautions that subretinal delivery may limit commercial uptake and suprachoroidal delivery data presented to date is still early. The analyst says the first functional results for RGX-202 in Duchenne muscular dystrophy will be shared in a company webcast on Monday.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX: